Johnson & Johnson Reports 2017 Third-Quarter Results:

Go back to Johnson & Johnson Reports 2017 Third-Quarter Results:

Johnson & Johnson (JNJ) PT Raised to $145 at Morgan Stanley

October 18, 2017 7:49 AM EDT

Morgan Stanley raised its price target on Johnson & Johnson (NYSE: JNJ) to $145.00 (from $140.00) while maintaining a Overweight rating.

... More

Johnson & Johnson (JNJ) PT Raised to $161 at Jefferies

October 18, 2017 7:30 AM EDT

Jefferies raised its price target on Johnson & Johnson (NYSE: JNJ) to $161.00 (from $160.00) while maintaining a Buy rating following beat and raise results.

Analyst Jeffrey Holford notes their revenue and adjusted EPS estimates remain well above consensus.

"The Pharma division remains under-modeled by... More

Johnson & Johnson (JNJ) PT Raised to $165 at Leerink Partners

October 18, 2017 7:03 AM EDT

Leerink Partners raised its price target on Johnson & Johnson (NYSE: JNJ) to $165.00 (from $150.00) while maintaining a Outperform rating.

Analyst Danielle Antalffy said outperformance highlights momentum. 217/2018 outlook moves higher.

... More

Johnson & Johnson (JNJ) Tops Q3 EPS by 10c; Raises Outlook

October 17, 2017 6:42 AM EDT

Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $1.90, $0.10 better than the analyst estimate of $1.80. Revenue for the quarter came in at $19.7 billion versus the consensus estimate of $19.28 billion.

GUIDANCE:

Johnson & Johnson raised its FY outlook. The company sees FY2017 EPS of... More